Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
The Bioinformatics for Next Generation Sequencing (BiNGS) Core, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Mount Sinai, New York, NY 10029, USA.
Trends Cancer. 2023 Jun;9(6):480-489. doi: 10.1016/j.trecan.2023.03.003. Epub 2023 Apr 5.
Cancer progression is a highly balanced process and is maintained by a sequence of finely tuned metabolic pathways. Stearoyl coenzyme A desaturase-1 (SCD1), the fatty enzyme that converts saturated fatty acids into monounsaturated fatty acids, is a critical modulator of the fatty acid metabolic pathway. SCD1 expression is associated with poor prognosis in several cancer types. SCD1 triggers an iron-dependent cell death called ferroptosis and elevated levels of SCD1 protect cancer cells against ferroptosis. Pharmacological inhibition of SCD1 as monotherapy and in combination with chemotherapeutic agents shows promising antitumor potential in preclinical models. In this review, we summarize the role of SCD in cancer cell progression, survival, and ferroptosis and discuss potential strategies to exploit SCD1 inhibition in future clinical trials.
癌症进展是一个高度平衡的过程,由一系列精细调节的代谢途径维持。硬脂酰辅酶 A 去饱和酶 1(SCD1)是一种将饱和脂肪酸转化为单不饱和脂肪酸的脂肪酶,是脂肪酸代谢途径的关键调节剂。SCD1 的表达与几种癌症类型的不良预后相关。SCD1 触发一种称为铁依赖性细胞死亡的 ferroptosis,并且高水平的 SCD1 可保护癌细胞免受 ferroptosis。SCD1 的药理学抑制作为单一疗法以及与化疗药物联合使用在临床前模型中显示出有前途的抗肿瘤潜力。在这篇综述中,我们总结了 SCD 在癌细胞进展、存活和 ferroptosis 中的作用,并讨论了在未来临床试验中利用 SCD1 抑制的潜在策略。